Innovent Biopharmaceutical Transformation
2021 Financials: Balance Sheet
IFRS-measure
RMB'million
Bank balances and cash
Other financial assets-current
Trade receivables
Deposits, prepayments and other receivables
As at 31 December
2021
8,377.1
2020
7,763.8'
Cash balance
644.8
357.3
968.4
475.4
213.3
164.5
As at 31 December 2021, our total cash
increased to RMB9,021 million
(equivalent to US$1.4 billion)
Inventories
1,347.2
705.7
Total Current Assets
11,550.8
9,466.7
Property, plant and equipment
2,693.0
1,584.1
Right-of-Use assets
396.9
327.1
Intangible assets
772.2
32.6
Equity instruments at fair value through other comprehensive income
203.4
Deposits for acquisition of property, plant and equipment
285.9
272.3
Other receivables and tax recoverables
127.7
139.3
Other financial assets
Total Non-current Assets
Total Assets
Trade payables
Other payables and accrued expenses
Contract liabilities
Borrowings
Lease liabilities
Tax payable
Total Current Liabilities
Contract liabilities
Government grants
Borrowings-non
Lease liabilities
213.8
12.9
4,692.9
2,368.3
16,243.7
11,835.0
(195.1)
(120.6)
(2,051.6)
(973.7)
(355.5)
(120.4)
(365.0)
(255.0)
(22.3)
(16.2)
(60.6)
(3,050.1)
(1,485.9)
(458.5)
(588.1)
(294.8)
(45.8)
(2,023.3)
(925.2)
(86.4)
(10.2)
Other financial liabilities
(0.3)
Total Non-current Liabilities
Total Liabilities
Total Equity
Innovent
(2,863.3)
(1,569.3)
(5,913.4)
(3,055.2)
10,330.4
8,779.8
Note: Numbers may not add due to rounding
Confidential
Copyright©2022 Innovent
12View entire presentation